Featured Platforms

Custom Protein Generation

Mammalian- Derived Products

Microbial- Derived Products

Antibody Drug Conjugates

Bispecific Ab Platform

Technologies & Platforms

Our Vision

“Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry

Our Mission

To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide

Our Company

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of June 30, 2020, there were a total of 286 integrated projects, including 141 projects in pre-clinical development stage, 125 projects in early-phase (phase I and II) clinical development, 19 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore exceeding 280,000 liters after 2023, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.

Learn more about our services & solutions

Our History

Originally established in 2010 as one of the WuXi AppTec business units, we supported the biologics industry by first offering cell line development and analytical protein characterization services. Over the course of the next 5 years the business unit steadily and aggressively added discovery, development, testing and GMP manufacturing capabilities and the necessary facilities and scientific personnel to provide the pharmaceutical industry the first true, open-access, single-source biologics technology platform from concept to commercialization. In 2015, WuXi Biologics was incorporated and in June 2017, WuXi Biologics went public on the Hong Kong Stock Exchange (HKEX) becoming one of the top 10 IPOs on the HKEX that year.


  • May 2010: WuXi Biologics’ Wuxi site (WuXi Biologics Co., Ltd.) was registered in Wuxi in Jiangsu Province
  • Oct 2012: WuXi Biologics’ Wuxi site was put into operation as the first cGMP biologics facility in China
  • Nov 2013: Successful completion of the first 2,000 L disposable bioreactor run using an NS0 cell line, marking an industry milestone
  • May 2014: 1st non-state affiliated biosafety testing laboratory in Asia (related story)
  • Dec 2015: Strategic alliance with AstraZeneca to expedite development of AstraZeneca’s innovative biologics portfolio in China
  • March 2016: 1st innovative antibody drug conjugate (ADC) development/manufacturing partnership in China
  • March 2016: 1st biologics manufactured in China for use in a European clinical trial
  • March 2016: 1st biological product (ADC) manufactured in China for use in an Australian clinical trial
  • May 2016: 1st sterile biologic product manufactured in China for use under a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) filing
  • Jan 2016: 1st integrated biologics R&D center in China providing service platform from discovery to clinic
  • Sept 2016: WuXi Biologics constructs Asia’s largest perfusion biologics manufacturing facility using disposable bioreactors
  • June 2017: WuXi Biologics conducts IPO and is officially listed on the Hong Kong Stock Exchange
  • Dec 2017: WuXi Biologics initiates cGMP manufacturing in the world’s largest biologics manufacturing facility using only single-use bioreactors
  • May 2018: WuXi Biologics announces plan to invest S$80 Million to establish a biologics manufacturing facility in Singapore
  • June 2018: WuXi Biologics announces plan to invest $60 Million to establish a biologics production facility in Worcester, Massachusetts, in the United States
  • June 2018: WuXi Biologics initiates construction of a state-of-the-art integrated ADC solution center
  • August 2018: WuXi Biologics selected into the Hang Seng HK 35 Index
  • Oct 2018: WuXi Biologics commences construction of 48,000L biologics commercial manufacturing center in Shijiazhuang
  • Nov 2018: WuXi Biologics commences construction of 1.6 million sq. ft. biologics innovation center in Shanghai
  • Dec  2018: WuXi Biologics commences construction of the largest biomanufacturing facility using single-use bioreactors in Ireland
  • Dec 2018: WuXi Biologics achieves breakthrough titer of 51g/L in cell culture productivity
  • March 2019: 1st Biologics company in China approved by both U.S. FDA and European Medicines Agency (EMA).
  • May 2019: WuXi Biologics signs letter of intent for long-term vaccine manufacturing contract

Awards & Recognition